PMID- 10834181
OWN - NLM
STAT- MEDLINE
DCOM- 20000801
LR  - 20131121
IS  - 0914-5087 (Print)
IS  - 0914-5087 (Linking)
VI  - 35
IP  - 5
DP  - 2000 May
TI  - [Risk factors for thromboembolism in patients with atrial fibrillation during 
      treatment with aspirin: a multicenter, cooperative retrospective study. Research 
      Group for Antiarrhythmic Drug Therapy].
PG  - 373-9
AB  - Warfarin is effective in preventing thromboembolism in patients with atrial 
      fibrillation, but aspirin is frequently used as an alternative treatment. A 
      multicenter, retrospective study was undertaken to identify patients at risk for 
      thromboembolism during treatment with aspirin. The study group consisted of 470 
      patients (318 males, 152 females, mean age 59.9 +/- 11.8 years at initial 
      examination) with atrial fibrillation who were treated with aspirin. Thirty-seven 
      percent of patients had paroxysmal atrial fibrillation and 65% of patients 
      received aspirin at a daily dose of 81 mg. Thromboembolism occurred in 31 
      patients (6.6%) during the follow-up period, resulting in cerebral infarction in 
      19 patients, transient ischemic attack in 7, and embolism of peripheral arteries 
      in 5. Patients with thromboembolism had lower prevalence of New York Heart 
      Association (NYHA) functional class I (52% vs 72%, p < 0.02) and paroxysmal 
      atrial fibrillation (23% vs 38%, p = 0.085) compared with patients without 
      thromboembolism. Multivariate analysis with the Cox proportional hazard model 
      determined age (> or = 65 years, relative risk 2.29, p = 0.032) as an independent 
      risk factor. NYHA functional class (> or = class II) tended to indicate an 
      increased risk of thromboembolic events (relative risk 1.90, p = 0.076). These 
      results suggest that aspirin has limited efficacy for prevention of 
      thromboembolism in patients with atrial fibrillation who are old (> or = 65 
      years) or have symptomatic heart failure.
LA  - jpn
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Age Factors
MH  - Analysis of Variance
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Atrial Fibrillation/*drug therapy
MH  - Female
MH  - Heart Diseases/complications
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Thromboembolism/*prevention & control
EDAT- 2000/06/02 09:00
MHDA- 2000/08/06 11:00
CRDT- 2000/06/02 09:00
PHST- 2000/06/02 09:00 [pubmed]
PHST- 2000/08/06 11:00 [medline]
PHST- 2000/06/02 09:00 [entrez]
PST - ppublish
SO  - J Cardiol. 2000 May;35(5):373-9.